AU2016318773B2 - Genetic engineering of macrophages for immunotherapy - Google Patents

Genetic engineering of macrophages for immunotherapy Download PDF

Info

Publication number
AU2016318773B2
AU2016318773B2 AU2016318773A AU2016318773A AU2016318773B2 AU 2016318773 B2 AU2016318773 B2 AU 2016318773B2 AU 2016318773 A AU2016318773 A AU 2016318773A AU 2016318773 A AU2016318773 A AU 2016318773A AU 2016318773 B2 AU2016318773 B2 AU 2016318773B2
Authority
AU
Australia
Prior art keywords
alternatives
cell
protein
cells
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016318773A
Other languages
English (en)
Other versions
AU2016318773A1 (en
Inventor
Courtney Crane
Michael C. Jensen
Nicole Lieberman
Kara WHITE MOYES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of AU2016318773A1 publication Critical patent/AU2016318773A1/en
Application granted granted Critical
Publication of AU2016318773B2 publication Critical patent/AU2016318773B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016318773A 2015-09-09 2016-09-07 Genetic engineering of macrophages for immunotherapy Active AU2016318773B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216224P 2015-09-09 2015-09-09
US62/216,224 2015-09-09
US201662361348P 2016-07-12 2016-07-12
US62/361,348 2016-07-12
PCT/US2016/050552 WO2017044487A1 (en) 2015-09-09 2016-09-07 Genetic engineering of macrophages for immunotherapy

Publications (2)

Publication Number Publication Date
AU2016318773A1 AU2016318773A1 (en) 2018-04-12
AU2016318773B2 true AU2016318773B2 (en) 2024-08-01

Family

ID=58240865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016318773A Active AU2016318773B2 (en) 2015-09-09 2016-09-07 Genetic engineering of macrophages for immunotherapy

Country Status (9)

Country Link
US (3) US10525082B2 (enExample)
EP (1) EP3347026A4 (enExample)
JP (3) JP6959909B2 (enExample)
CN (1) CN108243607A (enExample)
AU (1) AU2016318773B2 (enExample)
CA (1) CA2997912A1 (enExample)
HK (1) HK1257460A1 (enExample)
SG (1) SG10201913151TA (enExample)
WO (1) WO2017044487A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10525082B2 (en) * 2015-09-09 2020-01-07 Seattle Children's Hospital Genetic engineering of macrophages for immunotherapy
MY194135A (en) 2016-02-04 2022-11-14 Zhenglun Zhu Treatment and diagnosis of inflammatory disorders
EP4212169A1 (en) 2016-03-25 2023-07-19 PeriphaGen, Inc. High-transducing hsv vectors
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
JP2020516654A (ja) * 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
CN110913871B (zh) * 2017-05-17 2024-02-23 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN111527209B (zh) * 2017-11-01 2024-11-12 爱迪塔斯医药股份有限公司 Crispr-cas9编辑t细胞中的tgfbr2以用于免疫疗法的方法、组合物和组分
EP3710016A4 (en) * 2017-11-17 2021-12-01 Memorial Sloan-Kettering Cancer Center METHODS AND COMPOSITIONS FOR RELIEVING CYTOCINE RELEASE SYNDROME
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019195420A1 (en) 2018-04-04 2019-10-10 Nant Holding IP, LLC Advanced avartar dendritic cells
CA3291067A1 (en) * 2018-04-12 2025-11-29 Kite Pharma, Inc. Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
GB2587970B (en) 2018-04-19 2023-02-08 Univ California Compositions and methods for gene editing
US12410231B2 (en) 2018-05-07 2025-09-09 Board Of Regents Of The University Of Texas System Natural killer cell products and methods
EP3820485A4 (en) 2018-05-15 2022-05-11 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES
US20210254068A1 (en) * 2018-06-19 2021-08-19 Regents Of The University Of Minnesota Genome engineering primary monocytes
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN108823171A (zh) * 2018-07-24 2018-11-16 武汉赛云博生物科技有限公司 一种基因工程细胞及体外高效扩增nk细胞的方法
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
GB201818110D0 (en) * 2018-11-06 2018-12-19 Macrophox Ltd Monocytes for cancer targeting
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019384145A1 (en) * 2018-11-20 2021-06-10 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof
US20220056479A1 (en) * 2018-12-17 2022-02-24 Cure Genetics Co., Ltd. Method For Delivering Gene In Cells
CN113508178A (zh) * 2019-02-01 2021-10-15 西雅图儿童医院（Dba西雅图儿童研究所） 用于调节经工程化的基因的表达的微环境传感器
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3131017C (en) * 2019-02-27 2025-05-13 Actym Therapeutics, Inc. Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 改変細胞の増幅およびその応用
CA3135165A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110760480B (zh) * 2019-07-09 2021-07-02 杭州师范大学 一种抗肿瘤nk细胞及其制备方法
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
JP2022548069A (ja) * 2019-09-11 2022-11-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラ直交受容体タンパク質および使用方法
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2021064655A1 (en) * 2019-10-02 2021-04-08 Massachusetts Institute Of Technology High-throughput genetic screening
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN111150748A (zh) * 2019-12-27 2020-05-15 杭州荣谷生物科技有限公司 重组溶瘤病毒在制备治疗消化道癌药物中的用途
CN111087460B (zh) * 2020-01-14 2021-07-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种广谱型抗菌肽及其应用
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
MX2022011673A (es) 2020-03-20 2022-12-13 Lyell Immunopharma Inc Nuevos marcadores de superficie celular recombinantes.
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
GB202007906D0 (en) 2020-05-27 2020-07-08 Univ Edinburgh Method of transfecting macrophages
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
KR20230042691A (ko) 2020-06-04 2023-03-29 카리스마 테라퓨틱스 인코포레이티드 키메라 항원 수용체에 대한 신규한 작제물
EP4189074A4 (en) * 2020-06-22 2025-01-15 Nanjing Legend Biotech Co., Ltd. GENETICALLY MODIFIED GAMMA DELTA T CELLS FOR IMMUNOTHERAPY
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
WO2022165260A1 (en) * 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
JP2024527593A (ja) * 2021-07-09 2024-07-25 レジェンド バイオテック アイルランド リミテッド 変異型ｉｌ－１５組成物及びその方法
WO2023053828A1 (ja) * 2021-09-30 2023-04-06 テルモ株式会社 化学療法制御装置、化学療法制御システム、化学療法制御装置の制御方法及び化学療法制御プログラム
US20250000974A1 (en) * 2021-10-27 2025-01-02 The Regents Of The University Of California Combination of human natural killer cells and macrophages for cancer therapy
CN114404600B (zh) * 2022-01-21 2023-06-27 首都医科大学附属北京同仁医院 一种用于治疗肿瘤的药物组合及其应用
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用
WO2023205661A2 (en) * 2022-04-18 2023-10-26 Candel Therapeutics, Inc. Compositions and methods for viral vectors
WO2023205657A2 (en) * 2022-04-18 2023-10-26 City Of Hope Compositions for restoring mecp2 gene function and methods of use thereof
WO2024215990A2 (en) * 2023-04-13 2024-10-17 William Marsh Rice University Regulated cells expressing cytokines
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer
WO2026062037A1 (en) 2024-09-18 2026-03-26 Myllia Biotechnology Gmbh Gene perturbation in human monocyte-derived macrophages
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof
CN119020422A (zh) * 2024-10-28 2024-11-26 昆明医科大学 一种稳转萤火虫萤光素酶靶细胞株的构建方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046083A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US7432351B1 (en) * 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
IN2014DN06624A (enExample) * 2005-10-18 2015-07-10 Univ Colorado
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9023648B2 (en) * 2009-12-30 2015-05-05 University Of Massachusetts Method of transducing non-dividing myeloid cells utilizing chimeric murine leukemia viruses containing Vpx
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
PL3824905T3 (pl) * 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
HK1219980A1 (zh) * 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
CN108025024B (zh) 2015-07-28 2022-11-29 宾夕法尼亚大学董事会 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
US10525082B2 (en) 2015-09-09 2020-01-07 Seattle Children's Hospital Genetic engineering of macrophages for immunotherapy

Also Published As

Publication number Publication date
EP3347026A1 (en) 2018-07-18
WO2017044487A1 (en) 2017-03-16
CA2997912A1 (en) 2017-03-16
US20240091256A1 (en) 2024-03-21
US20170087185A1 (en) 2017-03-30
CN108243607A (zh) 2018-07-03
JP2018528774A (ja) 2018-10-04
US11826384B2 (en) 2023-11-28
AU2016318773A1 (en) 2018-04-12
JP2023109956A (ja) 2023-08-08
JP6959909B2 (ja) 2021-11-05
SG10201913151TA (en) 2020-03-30
JP7298103B2 (ja) 2023-06-27
HK1257460A1 (zh) 2019-10-18
JP2021118723A (ja) 2021-08-12
US10525082B2 (en) 2020-01-07
US20200155597A1 (en) 2020-05-21
EP3347026A4 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
US20240091256A1 (en) Genetic engineering of macrophages for immunotherapy
JP7412885B2 (ja) 細胞の異なる亜型の活性を選択的にモジュレートするための方法
Moyes et al. Genetically engineered macrophages: a potential platform for cancer immunotherapy
JP2022024158A (ja) カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
US20180161371A1 (en) Engineered natural killer cells and uses thereof
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
JP2023053328A (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
CN116745427A (zh) 用于递送多种多核苷酸的载体系统及其用途
US20210077554A1 (en) Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells
EP4670732A1 (en) METHOD FOR TREATMENT OF TUMORS USING A COMBINATION OF ONCOLYTIC VIRUS VACCINE AND IMMUNE CELLS
CN119998322A (zh) 基因编辑靶基因以增强自然杀伤细胞功能
JP2024038512A (ja) がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品
US20220064672A1 (en) Engineered oncolytic viruses expressing pd-l1 inhibitors and uses thereof
CA3244649A1 (en) IMMUNE CELLS WITH INACTIVATED SUV39H1 AND MODIFIED TCR
US20250319144A1 (en) Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy
WO2022210487A1 (ja) 抗原に特異的な受容体を発現する免疫細胞の製造方法
US20250228939A1 (en) Enhanced immune cell therapy
US20240366696A1 (en) Using reprogrammed, personalized cancer stem cells as a triple-killer cancer treatment
HK40127569A (zh) 用於肿瘤治疗的car修饰剂的产生
Xia Cancer Immunogene Therapy Using Viral Vectors Encoding Cytokines and Chimeric Antigen Receptors
HK40119904A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
CN121362259A (zh) 新型PDL1-CAR-γδT细胞的构建及其抗肿瘤应用
EA042086B1 (ru) Способы селективной модуляции активности отдельных подтипов клеток

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)